Patents Examined by Michael G. Hartley
  • Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
    Patent number: 11738088
    Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of: wherein L is a cleavable linker group; X is a cargo moiety-containing group; and R1 and R2 are each independently hydrogen, alkyl, or substituted alkyl; or R1 and R2 together form a boronic ester ring or a substituted boronic ester group.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 29, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Paul E. Floreancig, Alexander Deiters, Ramsey D. Hanna, Yuta R. Naro
  • Cyanine-containing compounds for cancer imaging and treatment
    Patent number: 11738095
    Abstract: This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: August 29, 2023
    Assignee: Emory University
    Inventors: Leland W. K. Chung, Lucjan Strekowski, Chunmeng Shi, Maged Henary, Gabor Patonay, James J. Krutak, Xiaojian Yang, Guodong Zhu, Ruoxiang Wang, Haiyen E. Zhau
  • Ocular drug delivery devices
    Patent number: 11730697
    Abstract: A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solution, including the API and solvent. The method may further include removing at least a portion of the absorbed solvent from the polymer by allowing the absorbed solvent to evaporate from the polymer or by drying the polymer. A variety of cellulose polymers may be used, including hydroxypropyl cellulose. A variety of APIs may be used, including Cyclosporine, Tobramycin and Vancomycin. Ocular delivery devices prepared by the methods may be used to treat a variety of eye disorders.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: August 22, 2023
    Assignees: Bausch Health Americas, Inc., Louisiana State University Agricultural and Mechanical College
    Inventors: Jean Theresa Jacob, Kevin John Halloran, Yuri McKee
  • Method of preventing the development of melanoma
    Patent number: 11730835
    Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: August 22, 2023
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Novak, Maxim V. Temnikov, Oleksandr Balakin
  • Plastic containers
    Patent number: 11730832
    Abstract: The present invention provides a method for the commercial presentation of a solution of gadolinium-DOTA that provides certain advantages over the known methods.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: August 22, 2023
    Assignee: GE HEALTHCARE AS
    Inventors: Karina Martha Langseth-Manrique, Arne Wang Aabye, Harald Laugen, Eva Krog Tamnes, Borge Mathisen
  • Methods and devices to generate [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides
    Patent number: 11707538
    Abstract: Described herein are methods and devices that allow the generation of [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides (such as [F-18]tosyl fluoride) in a manner that is suitable for radiosynthesis of F-18 labeled radiopharmaceuticals using currently available synthesis modules.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: July 25, 2023
    Assignee: Washington University
    Inventor: Dong Zhou
  • FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto
    Patent number: 11707539
    Abstract: The tumor stroma, which accounts for a large part of the tumor mass, represents an attractive target for the delivery of diagnostic and therapeutic compounds. Here, the focus is notably on a subpopulation of stromal cells, known as cancer-associated fibroblasts, which are present in more than 90% of epithelial carcinomas, including pancreatic, colon, and breast cancer. Cancer-associated fibroblasts feature high expression of FAP, which is not detectable in adult normal tissue but is associated with a poor prognosis in cancer patients. The present invention provides small-molecule radiopharmaceutical and imaging agents based on a FAP-specific inhibitor.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: July 25, 2023
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-sen Lai, Wengen Wu
  • DAZA chelators as ligands in liver imaging
    Patent number: 11701439
    Abstract: The invention relates to compounds according to the general formula (I) or a pharmaceutically acceptable salt of an inorganic or organic acid, a hydrate, a stereoisomer or a solvate thereof, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 being selected independently of one another from hydrogen and alkoxy. The compounds of formula (I) as ligands are suitable for the production of radioactively labelled 68Ga, 64Cu, 67Ga, 111In or 99mTc complexes. The invention further relates to a method for producing the compounds of formula (I) and the radioactively labelled complexes and to the use of the radioactively labelled complexes in imaging methods, such as PET/CT, in particular of the liver.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 18, 2023
    Assignee: X-NUCLEAR DIAGNOSTICS GMBH
    Inventors: Martin Freesmeyer, Julia Greiser
  • Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
    Patent number: 11696686
    Abstract: The invention is directed to methods for diagnosing reperfusion/non-reperfusion hemorrhage and predicting cardiac arrhythmias and sudden cardiac death in subjects comprising using imaging techniques to detect regional iron oxide deposition. The invention also provides treatment methods for subject at increased risk of sudden cardiac death.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: July 11, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Rohan Dharmakumar, Ivan Cokic
  • Methods and compounds for detection and binding of aldehydes
    Patent number: 11696960
    Abstract: Methods of detecting an aldehyde-containing compound in a subject or in a sample from a subject are described herein, comprising administering an aldehyde-binding compound of Formula I to the subject, or combining such a compound with the sample; and detecting the product of the compound of Formula I and the aldehyde-containing compound. Detection of the product may involve imaging, such as MRI, CEST-MRI or positron emission tomography (PET) imaging; or may involve fluorescence or an electrochemical detection method. Biologically relevant aldehydes detected according to the described method can be used to monitor conditions such as brain injury, neurodegenerative disorders such as Alzheimer's disease, diabetes, heart disease, and cancer.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: July 11, 2023
    Assignee: UNIVERSITY OF OTTAWA
    Inventors: Adam Shuhendler, Mojmir Suchy, Trina Dang
  • Multinuclear complexes and their preparation
    Patent number: 11690923
    Abstract: Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ligand is coordinated to the transition metal and the radioisotope to link the transition metal and the radioisotope and pendent ligands are coordinated to each of the transition metal and the radioisotope to stabilise the complex. The multinuclear complexes may include a radioisotope or radioelement that can be detected by medical equipment and may find use in therapy and/or the diagnosis of disease in patients.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: July 4, 2023
    Assignees: UNIVERSITY OF THE FREE STATE, UNIVERSITAT ZURICH
    Inventors: Andreas Roodt, Roger Ariel Alberto, Angelo Frei, Petrus Pennie Mokolokolo, Robin Kim Bollinger, Alice Brink, Dumisani Vincent Kama
  • Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
    Patent number: 11690524
    Abstract: The invention provides various methods of identifying myocardial infarction (MI) patients who have microvascular obstruction (MO), persistent microvascular obstruction (PMO), reperfusion hemorrhage, iron deposition, chronic iron deposition, and/or fat infiltration/accumulation. The invention provides various methods of identifying myocardial infarction (MI) patients who are at risk of prolonged inflammation burden in heart, adverse cardiac remodeling, electrical abnormality, mechanical abnormality, malignant cardiac arrhythmia, ischemic heart failure, and/or sudden cardiac death. The invention also provides various methods of treating these MI patients with chelation drugs, anti-inflammatory drugs, fat-lowering drugs, cooling therapies, or device therapies, or their combinations.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: July 4, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Rohan Dharmakumar, Ivan Cokic
  • Chelating AAZTA conjugates and complexes thereof
    Patent number: 11684682
    Abstract: A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their use as diagnostic or therapeutic agents.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: June 27, 2023
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Zsolt Baranyai, Simona Ghiani, Alessandro Maiocchi, Ivan Hawala
  • Astatine solution and method for producing same
    Patent number: 11684683
    Abstract: The invention provides a method for producing a solution containing 211At? (astatide ion) at a high radiochemical purity by using 211At obtained by a nuclear reaction as a starting material, including a step of adding a reducing agent to a solution containing an impurity derived from 211At. The invention also provides a solution containing 211At? (astatide ion) at a radiochemical purity of not less than 30%.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: June 27, 2023
    Assignee: OSAKA UNIVERSITY
    Inventors: Yoshifumi Shirakami, Tadashi Watabe, Kazuko Kaneda, Eku Shimosegawa, Atsushi Shinohara, Jun Hatazawa
  • Nanoparticle-alginate gels for X-ray imaging of the vasculature
    Patent number: 11672875
    Abstract: Disclosed are capped nanoparticles that are effectively trapped within an aqueous gelling solution to produce stable gels and function as a contrast agent for vascular imaging. The contrast agent has good radioopacity, is inexpensive to produce, and is safe to handle. This provides a new method to image the fine vasculature of biological systems.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: June 13, 2023
    Assignee: Saint Louis University
    Inventors: Sarah McBride-Gagyi, Steven W. Buckner, Paul Jelliss, Mohammad Salauddin Kader
  • Anti-CD33 antibody-guided imaging and treatment of acute myeloid leukemia
    Patent number: 11666672
    Abstract: Disclosed is a non-invasive PET-CT imaging method for detecting acute myeloid leukemia (AML) or extramedullary disease (EMD) in a subject using a radioactive isotope-labeled anti-CD33 antibody. Also disclosed is a PET-CT imaged-guided method for treating AML or EMD.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: June 6, 2023
    Assignee: CITY OF HOPE
    Inventors: Susanta Kumar Hui, Paul J. Yazaki, Srideshikan Sargur Madabushi
  • Compounds for imaging tau proteins that accumulate in brain
    Patent number: 11667628
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: June 6, 2023
    Assignee: NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
  • One-step labeling of antibodies to high specific activity with actinium-225
    Patent number: 11660357
    Abstract: Provided herein is a one-step method for chelating actinium-225 to a construct comprising a chelator linked to a bio-molecule, such as, an antibody or monoclonal antibody, via a bifunctional ligand in, for example, a 3-arm configuration. Also provided are methods for increasing the radiochemical yield of an actinium-225-chelant-biomolecule complex and for producing a high specific activity actinium-225 complex. The chelation is performed at a physiological temperature, about 37° C. Also provided are high specific activity actinium-225 complexes, that is, actinium-225 chelated to the chelator-biomolecule construct and pharmaceutical compositions thereof. Further provided are methods of treating a neoplastic disease or disorder with the actinium-225 complexes.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 30, 2023
    Inventors: David A. Scheinberg, Peter M. Smith-Jones, Michael R. McDevitt, William F. Maguire
  • PSMA-targeting compounds and uses thereof
    Patent number: 11661402
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: May 30, 2023
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • Nanoemulsion of iodinated fatty acids for CT imaging
    Patent number: 11654202
    Abstract: An iodinated CT contrast agent made of fatty acid derivatives for non-invasive visualisation and quantification of the brown and/or beige adipose tissue (BAT) or for imaging the heart and/or liver of a subject, to be taken orally which is a breakthrough in CT imaging. Image resolution by CT is significantly enhanced compared to PET.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: May 23, 2023
    Assignee: UNIVERSITY OF GENEVA
    Inventors: Laurent Vinet, Andrej Babic, Eric Allemann